Navigation Links
Infinity and MedImmune to Present Preclinical Data From Study of,Oral Formulation of IPI-504 At AACR

Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR

CAMBRIDGE, Mass. and GAITHERSBURG, Md., April 10, 2007 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) and MedImmune, Inc. (Nasdaq:MEDI) today announced that data from a preclinical study with an oral formulation of IPI-504 in non-small cell lung cancer (NSCLC) will be presented at the upcoming Annual Meeting of the American Association for Cancer Research (AACR) in Los Angeles, Calif., April 14-18, 2007. IPI-504, the companies' heat shock protein 90 (Hsp90) inhibitor, is currently being evaluated as a water-soluble, intravenous formulation in two disease-focused clinical trials involving patients with gastrointestinal stromal tumors (GIST) and NSCLC.

An oral presentation of the data, titled "IPI-504, a novel orally administered Hsp90 inhibitor, demonstrates anti-tumor effects in EGFR mutant, kinase inhibitor resistant NSCLC" (Abstract No. 5726) is scheduled to begin at 9:10 a.m. PDT on Wednesday, April 18, 2007 in Room 501 A-C in the Los Angeles Convention Center.

About IPI-504

IPI-504 is a small molecule drug candidate being developed jointly by Infinity and MedImmune. IPI-504 has been well-tolerated in its ongoing Phase I studies and has shown promising biological activity in a Phase I clinical trial in patients with relapsed, refractory Gleevec(r)-resistant GIST. IPI-504 is also being evaluated in a Phase I/II clinical trial in patients with advanced NSCLC. In preclinical studies, IPI-504 has been shown to inhibit Hsp90 potently and selectively, thereby killing cancer cells. IPI-504 has also demonstrated, in preclinical studies, broad potential to treat certain cancers as both a single agent as well as in combination with existing anti-cancer drugs. The water-based formulation of IPI-504 is delivered as an intravenous infusion; an oral formulation of IPI-504 is currently
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
3. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
4. MedImmune Announces Positive Clinical Results at PAS Annual Meeting From Large Prospective Trial in Prevention of Serious RSV Disease
5. Pediatric Academic Societies Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV
6. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
7. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
8. MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule
9. Micromet and MedImmune Present Data From Preclinical Study of New BiTE Molecule Targeting CEA
10. The Past, Present and Future of HLA Typing
11. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:10/22/2014)... Oct. 21, 2014 Influenza will affect as many ... the United States as high as ... to spread is from person to person in respiratory droplets ... serve way of death, but kills much fewer people each ... done by human fluids including sweat, saliva, blood and other ...
(Date:10/22/2014)... and AUSTIN, Texas , Oct. ... LLC today announced they have entered into a ... immunotherapies designed to target cancers. PhosImmune ... displayed on the surfaces of tumor cells in ... (PTTs), derived from proteins that play a role ...
(Date:10/22/2014)... SHANGHAI , Oct. 22, 2014   ... and WuXi PharmaTech (Cayman) Inc. (NYSE: WX ... comprehensive genomic profiling to biopharmaceutical companies conducting clinical trials ... Under the terms of the collaboration, Foundation Medicine will ... of Foundation Medicine,s FoundationOne® assay at the WuXi Genome ...
Breaking Medicine Technology:WholeHealth Products is proud to be releasing its Influenza A and B combo test, on the heels of the announcing of its phase 2 completion of the Rapid Ebola Test 2Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 3Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 4Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 5
... Healthy Advice ® Networks, the nation,s ... programs at point-of-care, announces that their partner, MediaForce ... the Food and Drug Administration,s campaign, educating consumers ... relievers. Partnering with MediaForce PR, Healthy Advice ...
... WuXi PharmaTech (Cayman) Inc. (NYSE: WX ... meeting of shareholders held in Hong Kong on August 9, ... the re-election of incumbent Class A directors Xiaozhong Liu, Ying ... term. About WuXi PharmaTechWuXi PharmaTech is a ...
Cached Medicine Technology:Healthy Advice® Networks Partners With MediaForce PR to Deliver Public Service Announcements to Educate Consumers About Appropriate Use of Prescription Medications 2Healthy Advice® Networks Partners With MediaForce PR to Deliver Public Service Announcements to Educate Consumers About Appropriate Use of Prescription Medications 3
(Date:10/22/2014)... October 22, 2014 Richard Carlson, Managing ... industry leader with over 25 years experience. Mr. ... in the areas related to EDI, B2B Commerce, RFID ... an Editorial Advisory Board member for Pharmaceutical Commerce Magazine ... Blue Fin Group is a management and technology consulting ...
(Date:10/22/2014)... Oct. 21, 2014 (HealthDay News) -- Two sisters in ... heart damage. Ilina and Medha Krishen use electronic ... sounds of trouble in breathing patterns or heartbeats. ... in Michigan, wanted to find a way to detect ... pollutants. Using an electronic stethoscope, Ilina recorded one breath ...
(Date:10/22/2014)... HealthDay Reporter , MONDAY, Oct. 20, ... tightened guidelines for health workers treating Ebola patients, now requiring ... a respirator at all times. The U.S. Centers for ... after two Dallas nurses contracted Ebola while caring for the ... Thomas Eric Duncan. Nina Pham is currently being treated for ...
(Date:10/20/2014)... Pittsburgh, PA (PRWEB) October 20, 2014 ... new, minimally-invasive procedure that enables physicians to repair a ... , The MitraClip system, developed by ... regurgitation (MR), a progressive and life-threatening condition in which ... allowing blood to flow backward from the heart’s left ...
(Date:10/20/2014)... 20, 2014 T.E.N., a technology ... announced today that William H. Murray, renowned author ... ISE® Luminary Leadership Award winner. Presented annually, the ... an outstanding leader and industry practitioner for his ... advancing the information security industry. , Formerly with ...
Breaking Medicine News(10 mins):Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4
... from Boston University School of Medicine (BUSM) have ... share the majority of the same genes with ... dysregulate the expression of circadian genes and those ... ,The circadian factors, including the principal circadian hormone ...
... of the anti-malarial drug hydroxychloroquine may help reduce ... diabetes . ,Type 2 diabetes mellitus ... its prevalence has been increasing. ... inexpensive treatment for an autoimmune disease such as ...
... A Canadian researcher has unearthed the relationship between high ... of circumstances , including among individuals with heart disease. ... Montreal Heart Institute, currently affiliated with the Universite de ... typically suffer chest pain during exercise, and may be ...
... admitted that she fears that an innocent kiss will result in ... she has major trust issues, and that she doesn't just make ... a waste of her time and kisses. ,Clarkson added ... ,"I have major trust issues. I just don't make ...
... looming global shortage of phosphorus can be dealt with by ... of the Institute for Sustainable Futures at the University of ... may finish in about 50 years. She believes that if ... a year is recycled, the danger of running out of ...
... ash and smoke into the air, seen in the ... causing more than 8000 people to be evacuated amid ... ,Officials raised the alert to the highest level on Tuesday ... Maluku, started spitting out flaming material, indicating magma was approaching ...
Cached Medicine News:Health News:Cocaine Exposure can Alter Neuronal Development in Zebrafish 2Health News:Anti-malarial Drug may Help Reduce Risk of Diabetes in Rheumatoid Arthritis Patients 2Health News:Urine is a Rich Source of Phosphorus 2Health News:Envisat Captured Breath of Volcano 2
... is a versatile, low profile, titanium ... Minimal instrumentation needed for implantation. Reduction ... Monosegmental and multisegmental applications. Worldwide market ... implantations. Tested in accordance with AS ...
... The ISOLA/VSP Spine System is a comprehensive ... that can be used for both deformity ... understanding of the spine in 3-dimensions, the ... translation techniques to correctly align and stabilize ...
Transcranial and peripheral vascular doppler system....
One channel transcranial doppler with multigate, emboli detection, monitoring module and tests for hemodynamic evaluation. Looki 1TC is suitable as well for routine diagnosis as for monitoring in ope...
Medicine Products: